DelveInsight’s, “Soft Tissue Sarcoma Pipeline Insight, 2023,” report provides comprehensive insights about 130+ companies and 130+ pipeline drugs in the Soft Tissue Sarcoma pipeline landscape. It covers the Soft Tissue Sarcoma pipeline drug profiles, including Soft Tissue Sarcoma clinical trials and nonclinical stage products. It also covers the Soft Tissue Sarcoma pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
For Soft Tissue Sarcoma emerging drugs, the Soft Tissue Sarcoma pipeline analysis report provides a 360° view of the therapeutics landscape by development point, product type, route of administration, molecule type, and MOA. The Soft Tissue Sarcoma pipeline research covers business opportunities, challenges, future partnerships, strong competitors, and growth strategies.
In the Soft Tissue Sarcoma Pipeline Report, a detailed description of the drug is given which includes the mechanism of action of the drug, Soft Tissue Sarcoma clinical trials studies, Soft Tissue Sarcoma NDA approvals (if any), and product development activities comprising the technology, Soft Tissue Sarcoma collaborations, licensing, mergers and acquisition, funding, designations, and other product-related details.
Key takeaways from the Soft Tissue Sarcoma Pipeline Report
- Over 130+ Soft Tissue Sarcoma companies are evaluating 130+ Soft Tissue Sarcoma pipeline therapies in various stages of development, and their anticipated acceptance in the Soft Tissue Sarcoma market would significantly increase market revenue.
- The leading Soft Tissue Sarcoma Companies such as NanoCarrier, Philogen, Lytix Biopharma, Karyopharm Therapeutics, Genentech, Nanobiotix, Boehringer Ingelheim, Eisai, Daiichi Sankyo, Hutchison MediPharma, Merck & Co, Incyte Corporation, Pfizer, Rafael Pharmaceuticals, NewVac, Hillstream BioPharma, Taiwan Liposome Company, Shanghai Junshi Biosciences, AstraZeneca, Monopar Therapeutics, Adaptimmune, GlaxoSmithKline, AVEO Oncology, Novartis, Kyowa Kirin, Macrogenics, Merrimack Pharmaceuticals, Chia Tai Tianqing Pharmaceutical Group, Bristol-Myers Squibb, SYZ Cell Therapy, Presage Biosciences, Cebiotex, Cyteir Therapeutics, Apexigen, BioAtla, Guangdong Xiangxue Precision Medical among, andothers.
- Promising Soft Tissue Sarcoma Pipeline Therapies such as AL3818, L19 TNF, NBTXR3, GPX-150, LTX-315, Nivolumab, Lenvatinib, Durvalumab, Nintedanib, and others
- The Soft Tissue Sarcoma Companies and academics are working to assess challenges and seek opportunities that could influence Soft Tissue Sarcoma R&D. The Soft Tissue Sarcoma pipeline therapies under development are focused on novel approaches to treat/improve Soft Tissue Sarcoma.
To explore more information on the latest breakthroughs in the Soft Tissue Sarcoma Pipeline treatment landscape of the report, click here @ Soft Tissue Sarcoma Pipeline Outlook
Soft Tissue Sarcoma Overview
Soft-tissue sarcoma (STS) are rare neoplasms that can develop in supporting or connective tissue, such as the muscle, nerves, tendons, blood vessels and fatty and fibrous tissues. They commonly affect the arms, legs, and trunk. They also appear in the stomach and intestines (GIST) as well as behind the abdomen (retroperitoneal sarcomas) and the female reproductive system (gynecological sarcomas). STSs may be classified according to the involved cell-type, the specific nature of the malignancy, and the disease’s clinical course. According to the World Health Organization (WHO), there are more than 50 histologic subtypes of STSs. The signs and symptoms of STSs vary greatly from patients to patients based on the type of STS. However, it is not associated with any noticeable symptoms early in the course of the disease but the affected individuals may notice slow-growing, painless mass in the affected area.
Latest Developmental Activities in the Soft Tissue Sarcoma Treatment Landscape
- In December 2020, Moleculin Biotech announced that FDA granted an orphan drug designation to annamycin for soft tissue sarcoma.
- In October 2020, Rafael Pharmaceuticals announced that the FDA has granted an Orphan Drug designation to CPI-613 (devimistat) for the treatment of soft tissue sarcoma.
- In July 2019, Monopar Therapeutics and the Spanish Sarcoma Group announced that they have entered into a clinical collaboration agreement to conduct a Phase 2 clinical trial to evaluate Monopar's investigational drug Camsirubicin in patients with advanced soft tissue sarcoma (ASTS).
- In March 2019, Italian cancer startup Philogen got off an impressive $70M funding round.
For further information, refer to the detailed Soft Tissue Sarcoma Unmet Needs, Soft Tissue Sarcoma Market Drivers, and Soft Tissue Sarcoma Market Barriers, click here for Soft Tissue Sarcoma Ongoing Clinical Trial Analysis
Soft Tissue Sarcoma Emerging Drugs Profile
AL3818: Advenchen Laboratories
AL3818 is a novel small molecule dual receptor tyrosine kinase inhibitor, which shows highly selective inhibition of fibroblast growth factor receptor (FGFR) and vascular endothelial growth factor receptor (VEGFR). Advenchen Laboratories, LLC is developing AL-3818 for the treatment of patients with advanced alveolar soft part sarcoma (ASPS), leiomyosarcoma (LMS), synovial sarcoma (SS), and soft-tissue sarcoma (STS). The drug is currently in the Phase III stage of development.
L19 TNF: Philogen
Onfekafusp alfa (L19 TNF) is a fully human recombinant fusion protein being developed by Philogen for the treatment of cancer, including gliomas, glioblastoma. It is a human antibody-cytokine fusion protein consisting of the non-covalent trimer of tumor necrosis factor (TNF) fused to an antibody specific to the extra-domain B of fibronectin (L19) in the single-chain variable fragment (scFv) format. The antibody-TNF fusion protein selectively localizes to tumor lesions following systemic administration. It is currently being studied in Phase III and Phase II of clinical development to treat STS patients in Europe and the United States, respectively.
NBTXR3: Nanobiotix
Hensify (NBTXR3), is a first-in-class nanoparticle radio-enhancer designed for direct injection into cancerous tumors and is engineered to increase the dose and efficacy of radiotherapy without increasing toxicity or causing damage to surrounding healthy tissues. NBTXR3 has the potential to improve radiotherapy efficacy by destroying locally advanced tumors more efficiently, improving the chance of full tumor resection. Treatment with NBTXR3 nanoparticles and radiotherapy in locally advanced STS aims to destroy tumors more efficiently, to facilitate surgery and enable complete malignant tissue extraction during surgery. Currently, it is in phase II/III stage of development.
GPX-150: Monopar Therapeutics
GPX-150, also known as camsirubicin, is a novel proprietary analog of the widely used cancer drug doxorubicin. Camsirubicin has been engineered specifically to retain the anticancer activity of doxorubicin while minimizing the toxic effects on the heart. The drug is currently being studied in the Phase II stage of development for the treatment of patients with STS.
LTX-315: Lytix Biopharma
Lytix’s product candidate LTX-315 is a first-in-class oncolytic peptide with the potential to fully personalize immunotherapy. LTX-315 is developed for the intratumoral treatment of solid tumors turning cold tumors hot. LTX-315 triggers the immune system to recognize, infiltrate and attack the cancer cells, opening up the tumor for various combination treatments, including the marketed checkpoint inhibitors.
Nivolumab: Bristol Myers Squibb
Nivolumab is a fully human IgG4 antibody targeting the immune checkpoint programmed death receptor-1 (PD-1). PD-L1 and PD-L2 ligands bind to the PD-1 receptor on T-cells, inhibiting the action of these cells. Tumor cells express PD-L1 and PD-L2 ligands on their surface. Nivolumab binds to PD-1, preventing PD-L1 and PD-L2 from inhibiting the action of T-cells, restoring a patient’s tumor-specific T-cell response. The clinical trials for nivolumab are currently ongoing in phase II for the treatment of patients with STS.
Lenvatinib: Merck sharp & Dohme Corp.
Lenvatinib is an orally available, multiple receptor tyrosine kinase (RTK) inhibitor with the novel binding mode that selectively inhibits the kinase activities of VEGFR-1, -2, and -3. The drug is currently being studied in Phase II in combination with pembrolizumab, a monoclonal antibody that binds to PD-1 and prevents its interaction with PD-1 and PD-2.
Durvalumab: AstraZeneca
Durvalumab is a human immunoglobulin G1 kappa (IgG1κ) monoclonal antibody and a novel immune checkpoint inhibitor for cancer treatment. The expression of PD-L1 is an adaptive immune response by tumor cells, resulting in overexpression of the molecule in some cancers. Durvalumab activates the immune responses mediated by cytotoxic T-cells that attack tumor cells by binding to PD-L1, thereby inhibiting its interaction with PD-1 on T-cells. The drug is currently in Phase II clinical trial for the treatment of patients with metastatic STS.
Nintedanib: Boehringer Ingelheim
Nintedanib is a small molecule that inhibits multiple receptor tyrosine kinases (RTKs) and non-receptor tyrosine kinases (nRTKs). Nintedanib inhibits the following RTKs: platelet-derived growth factor receptor (PDGFR) α and β, fibroblast growth factor receptor (FGFR) 1-3, vascular endothelial growth factor receptor (VEGFR) 1-3, colony-stimulating factor 1 receptor (CSF1R), and Fms-like tyrosine kinase-3 (FLT-3). These kinases, except for FLT-3 have been implicated in the pathogenesis of interstitial lung diseases (ILD). Nintedanib binds competitively to the adenosine triphosphate (ATP) binding pocket of these kinases and blocks the intracellular signaling cascades, which have been demonstrated to be involved in the pathogenesis of fibrotic tissue remodeling in ILD. Nintedanib also inhibits the following nRTKs: Lck, Lyn and Src kinases. The contribution of FLT-3 and nRTK inhibition to nintedanib efficacy in ILD is unknown. Currently, it is in phase 2 stage of development to treat soft tissue sarcoma.
Soft Tissue Sarcoma Pipeline Therapeutics Assessment
There are approx. 130+ key companies which are developing the therapies for Soft Tissue Sarcoma. The companies which have their Soft Tissue Sarcoma drug candidates in the most advanced stage, i.e. phase III include, Philogen.
Request a sample and discover the recent advances in Soft Tissue Sarcoma Ongoing Clinical Trial Analysis and Medications, click here @ Soft Tissue Sarcoma Treatment Landscape
Scope of the Soft Tissue Sarcoma Pipeline Report
- Coverage- Global
- Soft Tissue Sarcoma Companies- NanoCarrier, Philogen, Lytix Biopharma, Karyopharm Therapeutics, Genentech, Nanobiotix, Boehringer Ingelheim, Eisai, Daiichi Sankyo, Hutchison MediPharma, Merck & Co, Incyte Corporation, Pfizer, Rafael Pharmaceuticals, NewVac, Hillstream BioPharma, Taiwan Liposome Company, Shanghai Junshi Biosciences, AstraZeneca, Monopar Therapeutics, Adaptimmune, GlaxoSmithKline, AVEO Oncology, Novartis, Kyowa Kirin, Macrogenics, Merrimack Pharmaceuticals, Chia Tai Tianqing Pharmaceutical Group, Bristol-Myers Squibb, SYZ Cell Therapy, Presage Biosciences, Cebiotex, Cyteir Therapeutics, Apexigen, BioAtla, Guangdong Xiangxue Precision Medical among others.
- Soft Tissue Sarcoma Pipeline Therapies- AL3818, L19 TNF, NBTXR3, GPX-150, LTX-315, Nivolumab, Lenvatinib, Durvalumab, Nintedanib, and others
- Soft Tissue Sarcoma Pipeline Segmentation: Phases, Product Type, Mechanism of Action, Route of Administration
Dive deep into rich insights for drugs for Soft Tissue Sarcoma Market Drivers and Soft Tissue Sarcoma Market Barriers, click here @ Soft Tissue Sarcoma Unmet Needs and Analyst Views
Table of Content
- Introduction
- Soft Tissue Sarcoma Executive Summary
- Soft Tissue Sarcoma: Overview
- Soft Tissue Sarcoma Pipeline Therapeutics
- Soft Tissue Sarcoma Therapeutic Assessment
- Late Stage Products (Phase III)
- L19-TNF: Philogen
- Mid Stage Products (Phase II)
- Durvalumab: AstraZeneca
- Early Stage Products (Phase I/II)
- TBI-1301: Takara Bio
- Early Stage Products (Phase I)
- CEB-01: Cebiotex
- Preclinical and Discovery Stage Products
- HSB-114: Hillstream BioPharma
- Inactive Products
- Soft Tissue Sarcoma Key Companies
- Soft Tissue Sarcoma Key Products
- Soft Tissue Sarcoma- Unmet Needs
- Soft Tissue Sarcoma- Market Drivers and Barriers
- Soft Tissue Sarcoma- Future Perspectives and Conclusion
- Soft Tissue Sarcoma Analyst Views
- Soft Tissue Sarcoma Key Companies
- Appendix
Got Queries? Find out the related information on Soft Tissue Sarcoma Mergers and acquisitions, Soft Tissue Sarcoma Licensing Activities @ Soft Tissue Sarcoma Emerging Drugs, and Recent Trends
About Us
DelveInsight is a Business Consulting and Market research company, providing expert business solutions for the healthcare domain and offering quintessential advisory services in the areas of R&D, Strategy Formulation, Operations, Competitive Intelligence, Competitive Landscaping, and Mergers & Acquisitions.
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email:Send Email
Phone: 9193216187
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/consulting/due-diligence-services
